DS
SYRE icon

David Shaw’s Spyre Therapeutics SYRE Stock Holding History

David Shaw’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Buy
+26,452
New +$1.93M ﹤0.01% 3065
2022
Q3 		– Sell
-19,056
Closed -$241K – 5512
2022
Q2 		$241K Buy
19,056
+892
+5% +$31.3K ﹤0.01% 4462
2022
Q1 		$1.04M Buy
18,164
+9,064
+100% +$761K ﹤0.01% 3889
2021
Q4 		$1.08M Buy
9,100
+7,960
+698% +$1.26M ﹤0.01% 3862
2021
Q3 		$227K Sell
1,140
-699
-38% -$122K ﹤0.01% 4509
2021
Q2 		$320K Sell
1,839
-671
-27% -$122K ﹤0.01% 4246
2021
Q1 		$497K Sell
2,510
-1,959
-44% -$376K ﹤0.01% 3507
2020
Q4 		$879K Buy
4,469
+699
+19% +$145K ﹤0.01% 3100
2020
Q3 		$669K Buy
3,770
+52
+1% +$9.62K ﹤0.01% 3080
2020
Q2 		$860K Buy
3,718
+2,628
+241% +$501K ﹤0.01% 3032
2020
Q1 		$127K Buy
+1,090
New +$185K ﹤0.01% 3752
2019
Q3 		– Sell
-2,015
Closed -$345K – 4011
2019
Q2 		$345K Buy
2,015
+1,259
+167% +$218K ﹤0.01% 3254
2019
Q1 		$152K Buy
+756
New +$158K ﹤0.01% 3437

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

David Shaw's SYRE Position: Q2 2026 in Review

David Shaw opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 26,452 shares worth $2.35M. The stake represents ﹤0.01% of the portfolio and ranks #3065 among its holdings. This is a return to the name: David Shaw previously reported a position in SYRE as recently as Q2 2022.

David Shaw first reported a position in SYRE in Q1 2019 and has held it in 13 quarters since. 263 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • David Shaw held 26,452 shares of Spyre Therapeutics worth $2.35M as of Q2 2026.
  • Spyre Therapeutics was a new David Shaw position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3065 holding.
  • David Shaw first reported a position in Spyre Therapeutics in Q1 2019 and has held it in 13 quarters since.
  • 263 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.